<link rel="stylesheet" href="styles.cf390c6bfbe7555f.css">

Design, synthesis, and in vitro evaluation of BP-1-102 analogs with modified hydrophobic fragments for STAT3 inhibition

dc.contributor.authorOlekšák, Patrik
dc.contributor.authorPsotka, Miroslav
dc.contributor.authorVancurova, Marketa
dc.contributor.authorSapega, Olena
dc.contributor.authorBieblova, Jana
dc.contributor.authorReinis, Milan
dc.contributor.authorRysanek, David
dc.contributor.authorMikyskova, Romana
dc.contributor.authorChalupová, Katarína
dc.contributor.authorMaliňák, Dávid
dc.contributor.authorSvobodová, Jana
dc.contributor.authorAndrýs, Rudolf
dc.contributor.authorŘehulková, Helena
dc.contributor.authorŠkopek, Vojtěch
dc.contributor.authorPham, Ngoc Lam
dc.contributor.authorBartek, Jiri
dc.contributor.authorHodny, Zdenek
dc.contributor.authorMusílek, Kamil
dc.date.accessioned2025-12-05T09:51:04Z
dc.date.available2025-12-05T09:51:04Z
dc.date.issued2021
dc.description.abstractTwelve novel analogs of STAT3 inhibitor BP-1-102 were designed and synthesised with the aim to modify hydrophobic fragments of the molecules that are important for interaction with the STAT3 SH2 domain. The cytotoxic activity of the reference and novel compounds was evaluated using several human and two mouse cancer cell lines. BP-1-102 and its two analogs emerged as effective cytotoxic agents and were further tested in additional six human and two murine cancer cell lines, in all of which they manifested the cytotoxic effect in a micromolar range. Reference compound S3I-201.1066 was found ineffective in all tested cell lines, in contrast to formerly published data. The ability of selected BP-1-102 analogs to induce apoptosis and inhibition of STAT3 receptor-mediated phosphorylation was confirmed. The structure-activity relationship confirmed a demand for two hydrophobic substituents, i.e. the pentafluorophenyl moiety and another spatially bulky moiety, for effective cytotoxic activity and STAT3 inhibition.eng
dc.formatp. 410-424
dc.identifier.doi10.1080/14756366.2020.1871336
dc.identifier.issn1475-6366
dc.identifier.obd43877332
dc.identifier.urihttp://hdl.handle.net/20.500.12603/1191
dc.identifier.wos000607423800001
dc.language.isoeng
dc.peerreviewedyes
dc.publicationstatuspostprint
dc.publisherTaylor &amp; Francis
dc.relation.ispartofJournal of enzyme inhibition and medicinal chemistry, volume 36, issue: 1eng
dc.relation.publisherversionhttps://www.tandfonline.com/doi/full/10.1080/14756366.2020.1871336
dc.rights.accessOpen Access
dc.rights.licenseCC BY
dc.source.urlhttps://www.tandfonline.com/doi/full/10.1080/14756366.2020.1871336
dc.subjectSTAT3 signalling pathwayeng
dc.subjectcancereng
dc.subjectSH2 domaineng
dc.subjectinhibitoreng
dc.subjectstructure-activity relationshipeng
dc.titleDesign, synthesis, and in vitro evaluation of BP-1-102 analogs with modified hydrophobic fragments for STAT3 inhibitioneng
dc.typearticle

Soubory

Původní svazek

Nyní se zobrazuje 1 - 1 z 1
Načítá se...
Náhled
Název:
Oleksak,_JEIMC_2021.pdf
Velikost:
3,66 MB
Formát:
Adobe Portable Document Format